Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1,395.66 |
|---|---|
| High | 1,395.66 |
| Low | 1,395.66 |
| Bid | 1,390.00 |
| Offer | -- |
| Previous close | 1,381.00 |
| Average volume | 434.50 |
|---|---|
| Shares outstanding | 117.60m |
| Free float | 116.26m |
| P/E (TTM) | 16.49 |
| Market cap | 9.22bn USD |
| EPS (TTM) | 4.76 USD |
Data delayed at least 20 minutes, as of Feb 06 2026 18:17 GMT.
More ▼
Press releases
- Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
- Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
- Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
- Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
- U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
- Jim Lang Elected to Halozyme's Board of Directors
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
- Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
- Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
- Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
More ▼
